Faculty: Benjamin I. Goldstein, MD, PhD, FRCP(C)
Departments of Psychiatry, Pharmacology & Toxicology, University of Toronto
Director, Centre for Youth Bipolar Disorder
Director of Research, Department of Psychiatry
Scientist, Sunnybrook Research Institute, Sunnybrook Health Sciences Center
General Research Areas: Neuropharmacology/Psychopharmacology; Cardiovascular Pharmacology; Toxicology
Dr. Goldstein’s research focuses on bipolar disorder. Adolescents with bipolar disorder, or those at high clinical and/or familial risk of bipolar disorder, comprise the primary subject group. The primary areas of inquiry are the overlap between bipolar disorder and cardiovascular disease (CVD), and the identification of biomarkers for use in the assessment, monitoring, and treatment of these patients.
- To identify biomarkers that can inform clinical decisions in the area of adolescent bipolar disorder
- To gain knowledge regarding biological factors underlying the association between bipolar disorder and cardiovascular disease
- To identify novel objective treatment targets in bipolar disorder using neuroimaging (MRI) and neurocognitive phenotypes
Goldstein BI, Carnethon MR, Matthews KA, McIntyre RS, Miller GE, Raghuveer G, Stoney CM, Wasiak H, McCrindle BW; American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young. Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2015 Sep 8;132(10):965–86.
Hatch J, Andreazza A, Olowoyeye O, Rezin GT, Moody A, Goldstein BI. Cardiovascular and psychiatric characteristics associated with oxidative stress markers among adolescents with bipolar disorder. J Psychosom Res. 2015 Sep ;79(3):222–7.
Goldstein BI, Schaffer A, Wang S, Blanco C. Excessive and premature new-onset cardiovascular disease among adults with bipolar disorder in the US NESARC cohort. J Clin Psychiatry. 2015 Feb;76(2):163–9.
Goldstein BI, Young LT. Toward clinically applicable biomarkers in bipolar disorder: focus on BDNF, inflammatory markers, and endothelial function. Curr Psychiatry Rep.2013 Dec;15(12):425.
Goldstein BI, Collinger KA, Lotrich F, Marsland AL, Gill MK, Axelson DA, Birmaher B. Preliminary findings regarding proinflammatory markers and brain-derived neurotrophic factor among adolescents with bipolar spectrum disorders. J Child and Adolescent Psychopharmacology, 2011 Oct; 21(5):479-484.
Goldstein BI, Liu SM, Zivkovic N, Schaffer A, Chien LC, Blanco C. The burden of obesity among adults with bipolar disorder in the United States. Bipolar Disorders, 2011; 13:387-395.
Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry, 2009 Aug; 70(8):1078-1090.
Goldstein BI, Fagiolini A, Houck PR, Kupfer DJ. Prevalence and correlates of cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disorders, 2009; 11:657-662.
Goldstein BI, Birmaher B, Axelson DA, Goldstein TR, Esposito-Smythers C, Strober MA, Hunt J, Leonard H, Gill MK, Iyengar S, Grimm C, Yang M, Ryan ND, Keller MB. Preliminary findings regarding overweight and obesity in pediatric bipolar disorder. J Clin Psychiatry, 2008; 69:1953-1959.
Sunnybrook Health Sciences Centre
2075 Bayview Avenue, FG53